From Yahoo Finance: 2025-06-17 13:37:00

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is ranked among the best NASDAQ stocks under $50 to buy. Analysts at TD Cowen reiterated their Buy rating on AGIO, optimistic about the company’s mitapivat drug and upcoming trial results. The drug is expected to show significant reductions in vaso-occlusive crises (VOCs) for sickle cell disease (SCD), with potential sales of $4 billion.

TD Cowen named AGIO as its top small to mid-cap pick, anticipating a possible 100% increase in stock price by the end of the year. With the lead candidate FDA-approved and promising Phase 3 trial results, the company’s position in the emerging market is strong. AGIO, founded in 2007, focuses on discovering and developing treatments in cellular metabolism, aiming to improve and prolong lives.

While AGIO shows investment potential, other AI stocks may offer greater upside and less downside risk. For those seeking an undervalued AI stock benefiting from current trends, a free report on the best short-term AI stock is available. Consider exploring opportunities beyond AGIO for potential growth and diversification.



Read more at Yahoo Finance: Agios Pharmaceuticals, Inc. (AGIO) Backed by TD Cowen for Mitapivat’s Market Potential